| Literature DB >> 35465950 |
Benjamin Milne1, Joshua Lucas de Carvalho1, Salma Ayis2, Sanjay Chaubey3, Habib Khan3, Gudrun Kunst4.
Abstract
BACKGROUND: Preoperative frailty may predispose patients to poorer outcomes in cardiac surgery; however, there are limited data concerning how preoperative frailty predicts patient-centred outcomes, such as patient-reported disability. Our objective was to evaluate the association between preoperative frailty and postoperative disability.Entities:
Keywords: cardiac surgery; disability; frailty; patient-centred outcome; postoperative outcome
Mesh:
Year: 2022 PMID: 35465950 PMCID: PMC9204662 DOI: 10.1016/j.bja.2022.03.015
Source DB: PubMed Journal: Br J Anaesth ISSN: 0007-0912 Impact factor: 11.719
Preoperative characteristics and scoring, and operative characteristics. ACE, angiotensin-converting enzyme; ASA, American Society of Anesthesiologists; AVR, aortic valve repair/replacement; CABG, coronary artery bypass graft; CAF, comprehensive assessment of frailty score; CCS, Canadian Cardiovascular Society angina grade; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; FORECAST, frailty predicts death one year after cardiac surgery test score; IDDM, insulin-dependent diabetes mellitus; IQR, inter-quartile range; LVEF, left ventricular ejection fraction; MSK, musculoskeletal; MVR, mitral valve repair/replacement; NIDDM, non-insulin-dependent diabetes mellitus; NYHA, New York Heart Association functional classification; sd, standard deviation; WHODAS-12, WHO Disability Assessment Schedule 2.0: 12-Part Questionnaire (% score).
| Non-frail ( | Frail ( | ||
|---|---|---|---|
| ASA physical status, | |||
| Class 3 | 72 (72.7) | 29 (61.7) | 0.25 |
| Class 4 | 27 (27.3) | 18 (38.3) | |
| Age (yr), median [IQR] | 66.0 [58.0–72.5] | 71.0 [59.5–77.0] | 0.10 |
| Male sex, | 77 (77.8) | 30 (63.8) | 0.11 |
| BMI (kg m−2) mean ( | 28.4 (4.4) | 28.8 (5.5) | 0.67 |
| Race, | |||
| White | 84 (84.8) | 32 (68.1) | 0.03 |
| Asian | 9 (9.1) | 8 (17.0) | 0.26 |
| Black | 6 (6.1) | 7 (14.9) | 0.15 |
| Hypertension, | 72 (73) | 36 (77) | 0.77 |
| Hypercholesterolaemia, | 64 (65) | 31 (66) | 1.0 |
| Diabetes mellitus, | |||
| NIDDM | 19 (19) | 10 (21) | 0.94 |
| IDDM | 6 (6) | 7 (15) | 0.15 |
| Previous stroke, | 4 (4) | 7 (15) | 0.05 |
| Significant MSK/neurological disease, | 3 (3) | 8 (17) | 0.01 |
| Previous myocardial infarction, | 23 (23) | 8 (17) | 0.52 |
| Smoking, | |||
| Current | 9 (9) | 6 (13) | 0.70 |
| Previous | 51 (52) | 18 (38) | 0.19 |
| COPD, | 11 (11) | 5 (11) | 1.0 |
| Previous cardiac surgery, | 4 (4) | 6 (13) | 0.11 |
| LVEF, | |||
| >55% | 64 (65) | 28 (60) | 0.93 |
| 35–54% | 30 (30) | 14 (30) | 1.0 |
| <35% | 5 (5) | 5 (11) | 0.37 |
| Family history of ischaemic heart disease, | 59 (60) | 18 (38) | 0.03 |
| NYHA, modal class | 2 | 3 | 0.01 |
| Albumin (g L−1), mean ( | 41 (6) | 38 (6) | 0.04 |
| Aspirin use, | 62 (63) | 21 (45) | 0.06 |
| Beta-blocker use, | 60 (61) | 27 (57) | 0.86 |
| Statin use, | 68 (69) | 34 (72) | 0.80 |
| ACE inhibitor use, | 57 (58) | 36 (77) | 0.04 |
| Nitrate use, | 10 (10) | 7 (15) | 0.57 |
| Insulin use, | 6 (6) | 7 (15) | 0.15 |
| Metformin use, | 15 (15) | 9 (19) | 0.71 |
| CAF, median [IQR] | 7.5 [5.2–9.0] | 14.5 [12.5–20.8] | <0.001 |
| FORECAST, mean ( | 5.6 (2.0) | 9.8 (2.7) | <0.001 |
| WHODAS-12 (%), median [IQR] | 10.4 [5.2–16.7] | 31.3 [15.6–44.8] | <0.001 |
| Preoperative disability (WHODAS-12 ≥25%), | 11 (11) | 31 (66) | <0.001 |
| EuroSCORE II (%), median [IQR] | 1.2 [0.9–1.9] | 2.1 [1.2–3.0] | <0.001 |
| Surgery, | |||
| CABG | 62 (63) | 22 (47) | 0.10 |
| CABG+valve surgery | 10 (10) | 5 (11) | 0.10 |
| MVR | 7 (7) | 7 (15) | 0.23 |
| AVR | 15 (15) | 10 (21) | 0.49 |
| Other | 5 (5) | 3 (6) | 1.0 |
| Bypass time (min), median [IQR] | 92 [67.5–114.5] | 95 [67.5–119.5] | 0.91 |
| Cross-clamp time (min), median [IQR] | 60 [42.5–78] | 57 [46.6–76.5] | 0.75 |
| Off-pump surgery, | 16 (16) | 8 (17) | 1.0 |
Postoperative disability scores and disability-free survival in frail and non-frail patients. ∗n=134: non-frail=91; frail=43. †n=125: non-frail=86; frail=39. DFS, disability-free survival, indicated by WHODAS-12 score <25.0%; IQR, inter-quartile range; WHODAS-12, WHO Disability Assessment Schedule 2.0: 12-Part Questionnaire. Incidence compared with χ2 test or McNemar's test, and medians with Mann–Whitney U-test.
| Preoperative frailty assessment | ||||
|---|---|---|---|---|
| Non-frail | Frail | Total | ||
| Number of patients free of disability and alive (DFS), | ||||
| 1 Month∗ | 59 (64.8) | 17 (39.5) | 76 (56.7) | 0.01 |
| 3 Months† | 78 (90.7) | 27 (69.2) | 105 (84.0) | 0.01 |
| Median disability scores (%) [IQR], (WHODAS-12) | ||||
| Preoperative ( | 10.4 [5.2–16.7] | 31.3 [15.6–44.8] | 12.5 [6.3–26.6] | <0.001 |
| 1 Month∗ | 16.7 [6.3–29.2] | 29.2 [9.4–54.2] | 19.8 [6.3–37.0] | 0.01 |
| 3 Months† | 2.1 [0.0–12.0] | 14.6 [3.1–31.3] | 4.2 [0.0–16.7] | <0.001 |
| Change in median disability scores from baseline (%) [IQR] | ||||
| 1 Month∗ | +4.2 [–4.2–{+18.8}] | –2.1 [–9.4–{+13.6}] | +2.1 [–4.2–{+18.8}] | 0.04 |
| 3 Months† | –6.3 [–12.5–0.0] | –10.4 [–20.8–{–2.1}] | –8.3 [–14.6–0.0] | 0.02 |
Fig 1Consolidated Standards of Reporting Trials diagram.
Odds ratios for the association between preoperative CAF-based frailty and disability-free survival at 1 and 3 months. ∗Estimates adjusted for age and EuroSCORE II values for each patient in logistic model. CAF, comprehensive assessment of frailty; DFS, disability-free survival; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II. Odds ratios (ORs) and 95% confidence intervals (CIs) based on univariate logistic regression models.
| Preoperative frailty | Postoperative free of disability and alive (DFS) | Unadjusted estimates | Adjusted estimates∗ | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | ||||
| CAF score ≥11 | 1 Month | 0.33 | 0.15–0.72 | 0.006 | 0.64 | 0.29–1.09 | 0.177 |
| 3 Months | 0.23 | 0.08–0.62 | 0.004 | 0.51 | 0.24–0.89 | 0.045 | |
Fig 2Frailty group assignment and median disability (WHODAS-12) score (%; inter-quartile range) at baseline (n=146), 1 month (n=134), and 3 months (n=125). Frail patients: change from preoperative to 1 month (P=0.72) and 3 months (P=0.02). Non-frail patients: change from preoperative to 1 month (P=0.002) and 3 months (P<0.001). Asterisk (∗) denotes significant change from preoperative value (P<0.05). WHODAS-12, WHO Disability Assessment Schedule 2.0: 12-Part Questionnaire score.
Fig 3Empirical receiver operating characteristic (ROC) curves for the performance of unadjusted models of the CAF score, WHODAS-12 score, and EuroSCORE II to predict patients being free of disability and alive (DFS) at 3 months. Unadjusted (continuous) CAF score: AUC 0.72 [95% CI: 0.57–0.86] and optimal cut-off score 13.8 (sensitivity 91%; specificity 55%; accuracy 85%; NPV 52%; PPV 91%). (HL P-value: 0.2421). Unadjusted WHODAS-12 score: AUC 0.79 [95% CI: 0.69–0.90] and optimal cut-off score 24.0% (sensitivity 79%; specificity 75%; accuracy 78%; NPV 41%; PPV 94%). (HL P-value: 0.24). Unadjusted EuroSCORE II: AUC 0.62 [95% CI: 0.47–0.77] and optimal cut-off score 2.4% (sensitivity 80%; specificity 50%; accuracy 75%; NPV 32%; PPV 89.4%). (HL P-value: 0.9064). AUC, area under the curve; CAF, comprehensive assessment of frailty; CI, confidence interval; DFS, disability-free survival; EuroSCORE II, European System for Cardiac Operative Risk Evaluation II; HL P-value, Hosmer–Lemeshow goodness-of-fit test P-value; NPV, negative predictive value; PPV, positive predictive value; WHODAS-12, WHO Disability Assessment Schedule 2.0: 12-Part Questionnaire score (in % of the maximum disability score).